| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24d41624f4c12622605b7048517fe8f7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2011-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9f11a61d636733dba6a3b3f3d02feb65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4149ad410412a05f409b2f5c29e54db2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b5a796598c451b74a5d07a86e455420c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b6e92c4c869d5ca6b13f7bb77091164 |
| publicationDate |
2013-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20130095737-A |
| titleOfInvention |
SiRNA targeting VEEFA and treatment methods in vivo |
| abstract |
Vascular endothelial growth factor A (VEGFA) is a chemical signal produced by cells that stimulate the growth of new blood vessels, and VEGFA overexpression is an undesirable physiological condition. conditions). Through the identification of new siRNAs and modifications that improve their in vivo silencing ability, therapeutic compositions and methods have been invented to address the problems associated with such overexpression. |
| priorityDate |
2010-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |